Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X

Core Insights - Incannex Healthcare Inc. has achieved a significant milestone by locking the database for the RePOSA Phase 2 clinical trial of its lead drug candidate IHL-42X for obstructive sleep apnoea (OSA) as of June 16, 2025, with top-line results expected in July 2025 [1][2][3] Company Overview - Incannex is a clinical-stage biopharmaceutical company focused on developing combination drug therapies for high-impact indications, including OSA, rheumatoid arthritis, and generalized anxiety disorder [8] - The company is advancing three clinical-stage product candidates, with IHL-42X being the lead program designed to target the underlying mechanisms of OSA [8] Drug Development - IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide, currently in the RePOSA Phase 2/3 clinical trial, which aims to enroll over 560 patients globally [5][6] - The drug targets two physiological pathways associated with OSA, specifically intermittent hypoxia and hypercapnia, offering a differentiated approach compared to existing treatments [7] Market Potential - OSA affects over 900 million people worldwide, with growing awareness of its impact on cardiovascular and metabolic health, positioning IHL-42X to potentially disrupt the treatment paradigm [4][6] - Approximately 67% of individuals with OSA are not classified as obese, indicating a broader patient population that could benefit from IHL-42X [7] Clinical Trial Progress - The RePOSA Phase 2 trial is evaluating IHL-42X in patients with moderate to severe OSA who are unable or unwilling to use continuous positive airway pressure (CPAP) [3][4] - Previous studies have shown that IHL-42X can reduce the Apnea-Hypopnea Index (AHI) by an average of 51% relative to baseline in all dosage strengths [6]